Related Experiment Video
Updated: Aug 25, 2025

Modeling Intracerebral Hemorrhage in Mice: Injection of Autologous Blood or Bacterial Collagenase
Published on: September 22, 2012
Effects of Supplemental Dexmedetomidine Anesthesia on Intracranial Aneurysm Patients Undergoing Intracranial
Zhihong Li1, Qingwang Liu2, Junchao Yao1
1Department 5 of Neurosurgery, Cangzhou Central Hospital, Cangzhou, Hebei, China.
Insights
Dexmedetomidine (DEX) supplementation improved outcomes for patients undergoing intracranial aneurysm embolization. DEX reduced surgical stress and enhanced cognitive function, leading to better patient recovery.
Area of Science:
- Neuroscience
- Anesthesiology
- Neurosurgery
Background:
- Intracranial aneurysms (IA) affect 0.4%-3% of the population, causing significant mortality and subarachnoid hemorrhage.
- Investigating interventions to improve outcomes after IA treatment is crucial.
Purpose of the Study:
- To evaluate the impact of dexmedetomidine (DEX) as an anesthetic supplement on patient outcomes after intracranial interventional embolization.
- To assess DEX's effect on surgical stress markers and cognitive function.
Main Methods:
- A randomized controlled trial involving 96 patients with intracranial aneurysms.
- Patients received either standard anesthesia or anesthesia supplemented with DEX (0.6 μg/kg).
- Outcomes measured included Glasgow Outcome Scale, serum stress markers (norepinephrine, cortisol, IL-6, CRP), and cognitive function tests (MMSE, MoCA).
Main Results:
- DEX supplementation significantly reduced adverse reactions and surgical stress markers.
- Patients receiving DEX showed attenuated cognitive impairment after extubation.
- Improved Glasgow Outcome Scale scores were observed in the DEX group.
Conclusions:
- Dexmedetomidine (DEX) as an anesthetic supplement effectively reduces surgical stress in patients undergoing intracranial interventional embolization.
- DEX improves postoperative cognitive function and patient recovery.
- DEX is a beneficial adjunct for managing patients with intracranial aneurysms undergoing embolization.
Background:
Intracranial aneurysm (IA) has been identified in approximately 0.4%-3% of the population and associated with 3%-10% mortality. IA is the major factor attributing to spontaneous subarachnoid hemorrhage. We aim to investigate that whether employing dexmedetomidine (DEX), an α2 adrenergic receptor agonist, as a supplementation could impact the outcomes of patients with intracranial interventional embolization.
Methods:
Patients were randomly divided into a control group (n = 48 cases) and a DEX (0.6 μg/kg) supplement group (n = 48 cases). Patients' outcomes were evaluated using the Glasgow Outcome Scale. Serum levels of norepinephrine, cortisol, interleukin-6, C-reactive protein, neuron-specific enolase, and S100β were determined using enzyme-linked immunoassay. The cognitive function of patients was assessed using the Mini-Mental State Exam and Montreal Cognitive Assessment tests.
Results:
DEX supplementation during anesthesia reduced adverse reaction, surgical stress, and attenuated cognitive impairment after extubation in IA patients' postintracranial interventional embolization.
Conclusions:
Our study demonstrated that employing DEX as supplementation during anesthesia could effectively reduce surgical stress and improve cognitive function, ultimately improving patients' recovery from intracranial interventional embolization.
More Related Videos
Related Concept Videos
Aneurysm IV: Nursing Management
Parenteral Anesthetics: Overview
Local Anesthetics: Clinical Application as Epidural Anesthesia
Since epidural anesthetics can be infused through an epidural catheter, all types of drugs, including short-acting ones, can be administered. Chloroprocaine and lidocaine are examples of short and long-duration anesthetics, respectively. Bupivacaine...
Depolarizing Blockers: Pharmocokinetics
Aneurysm III: Interprofessional Care

